Trademark
Full logoAbout Biogen
Biogen is a biotechnology company focused on neurological diseases, including multiple sclerosis (Tysabri, Tecfidera), spinal muscular atrophy (Spinraza), Alzheimer's disease (Leqembi, in partnership with Eisai), and rare disease (Skyclarys). Founded in 1978 and headquartered in Cambridge, Massachusetts, the company is one of the oldest biotech companies in the world. Biogen's MS franchise has been pressured by biosimilars, while Leqembi launch trajectory and the Reata Pharmaceuticals acquisition (Skyclarys for Friedreich's ataxia) are central to the next chapter. The company also has a deep neuropsychiatry and rare disease pipeline.
About the Biogen logo
The Biogen (BIIB) logo is part of the Tickericons pack — a hand-crafted set of logos for every company in the S&P 500. Each logo is manually redrawn to a consistent grid, weight, and corner radius so BIIB sits cleanly next to other tickers in cap tables, dashboards, equity research, and fintech UI.
You get two styles: the trademark (just the symbol, ideal for grids and tight UI) and the full logo (mark plus wordmark, ideal when there's room to breathe). Both ship as scalable SVG, high-resolution PNG, and reusable Figma components.
Is Biogen in the S&P 500?
Yes. Biogen (BIIB) is a member of the S&P 500 and has been since Nov 13, 2003. It is classified under the Health Care sector. See every S&P 500 addition and removal.
Other Health Care companies
See all →
abtAbbott LaboratoriesMar 4, 195725,459
abbvAbbVieDec 31, 20125,068
aAgilent TechnologiesJun 5, 20009,660
algnAlign TechnologyJun 19, 20173,437
amgnAmgenJan 2, 199212,737
baxBaxter InternationalSep 30, 197219,770
bdxBecton Dickinson and CoSep 30, 197219,770
techBio-Techne CorporationAug 30, 20211,904
bsxBoston Scientific CorporationFeb 24, 199511,588
bmyBristol-Myers SquibbMar 4, 195725,459
Get all S&P 500 logos
One-time payment. SVG, PNG, and a Figma library. Free updates as the index changes.


